Aesica Consortium Wins Technology Strategy Board Grant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica Consortium Wins Technology Strategy Board Grant



Aesica’s consortium with Charnwood Technical Consulting, CatScI, and Biocatalysts, has won a Technology Strategy Board grant directed at funding sustainable, high-value chemical manufacturing achieved through industrial biotechnology. The winning project is focused on establishing an industrialbiotechnology process aimed at improving the sustainability of the manufacture of APIs.

The grant is designed to both assist commercial entities in trialing new processes and to create demonstration scale prototypes. The overall project, valued at £200,000 (approximately $335,000), is scheduled for completion in 2014.

The funding for the project meets the Technology Strategy Board’s objective of collaborations between chemical sectors and industrial biotechnology developers, combining biological and chemical practices. Biocatalysts will use design for manufacture principles to discover, develop, and manufacture new enzymes for the production of APIs. CatScI will perform the proof of concept studies to assess the feasibility of a value-adding new industrial biotechnology route to an API. Charnwood Technical Consulting will provide expertise to help design and scale-up the process, as well as guidance on quality and regulatory issues. Aesica will manage the overall project and carry out scale-up studies to determine the probability of the technology at larger scale.

Source: Aesica

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here